Tesamorelin and visceral fat: what the labeled trial evidence supports, and what it does not

Key takeaways

• Tesamorelin (Egrifta WR) is FDA-approved (2010) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label is narrow; off-label use is extrapolation.
• Pivotal phase 3 trials (Falutz 2007 NEJM, Falutz 2010 JCEM) reported approximately 15 percent visceral adipose tissue reduction over 26 weeks at 2 mg subcutaneous daily.
• Effect attenuates within months of discontinuation; tesamorelin is an ongoing-therapy intervention, not a curative course.
• IGF-1 monitoring is label-required because the GHRH-axis mechanism elevates IGF-1; pre-existing diabetes and impaired glucose tolerance need closer monitoring.
• Tesamorelin is WADA-prohibited under section S2 (peptide hormones / GHRH analogs) at all times in and out of competition.

What tesamorelin is, and what it is not

Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves enzymatic stability. It is not growth hormone itself. It is a secretagogue that prompts the pituitary to release endogenous growth hormone in a more physiologic pulsatile pattern than recombinant GH administration would .

FDA approval came in 2010 under the brand name Egrifta, with a single labeled indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The original Egrifta required complex reconstitution. The 2019 follow-on product Egrifta SV (Single Vial) simplified that process. Egrifta WR (water reconstitution) replaced earlier formulations and is the current product on the US market .

Mechanism: the GHRH axis, in plain language

GHRH binds the GHRHR receptor on anterior pituitary somatotrophs, triggering a cyclic-AMP cascade that releases stored growth hormone into circulation. GH then acts at the liver and peripheral tissues, where it stimulates IGF-1 synthesis. IGF-1 mediates many of the downstream metabolic and trophic effects attributed to GH.

Tesamorelin is engineered to resist degradation by dipeptidyl peptidase IV, the same enzyme that limits native GLP-1 activity. The longer half-life relative to native GHRH supports once-daily dosing while preserving pulsatile pituitary signaling. This mechanism distinguishes tesamorelin from direct GH replacement: endogenous feedback (somatostatin, IGF-1 negative feedback) remains intact.

The pivotal phase 3 program

Two pivotal phase 3 trials supported the FDA approval. The first, reported by Falutz and colleagues in 2007 in the New England Journal of Medicine, randomized 412 HIV patients with abdominal lipohypertrophy to tesamorelin 2 mg subcutaneously daily versus placebo for 26 weeks. Visceral adipose tissue (VAT) measured by single-slice CT decreased approximately 15 percent in the tesamorelin arm versus a small increase in placebo .

A second confirmatory phase 3 trial, published by Falutz and colleagues in 2010, replicated the VAT reduction in a separate cohort and showed that subjects who continued therapy through a 26-week extension preserved their reduction, while subjects who switched to placebo regained VAT toward baseline. This is the basis for the labeled posture that tesamorelin is an ongoing rather than curative therapy .

Pooled analyses of these trials reported modest improvements in triglycerides and total cholesterol alongside the VAT reduction, with no consistent change in HDL .

What the trials actually showed, line by line

• VAT reduction (CT) of approximately 15 percent over 26 weeks at 2 mg subcutaneous daily in HIV-associated lipodystrophy.
• Effect attenuates within months of discontinuation; continued dosing preserves the response.
• IGF-1 increases (label-noted, predictable from mechanism); a portion of subjects exceed the upper limit of normal for age.
• Triglyceride and total-cholesterol decreases in pooled analyses; HDL essentially unchanged.
• Common adverse events: injection-site reactions (~25 percent), arthralgia (~13 percent), peripheral edema, paresthesia, and headache.
• Serious adverse events were uncommon; rates of malignancy and cardiovascular events did not differ from placebo over the trial duration.

The NAFLD / hepatic steatosis signal

A separate 2014 randomized trial led by Stanley examined tesamorelin in HIV-infected adults with hepatic steatosis. The trial used MRI proton density fat fraction as the primary endpoint and reported a meaningful reduction in liver fat over 12 months in the tesamorelin arm versus placebo . A follow-up MRI-elastography substudy reported reductions in liver fibrosis markers in tesamorelin-treated subjects.

These data are encouraging but specific to the HIV population. They do not establish tesamorelin as a hepatic steatosis therapy in non-HIV adults. NAFLD trials in non-HIV populations have not been completed at sufficient scale to support a labeled indication, and any off-label use for liver fat in non-HIV adults is extrapolation rather than confirmation.

The off-label conversation

Outside the HIV-lipodystrophy population, tesamorelin appears in research-clinic discussion for general visceral adiposity, NAFLD-adjacent metabolic disease, and as a research probe for GH-axis activation. The published trial base outside HIV is small. Cross-population extrapolation should account for baseline GH-axis status, baseline IGF-1, and baseline insulin sensitivity, all of which differ from the HIV-lipodystrophy cohort that defined the label.

Visceral fat is also moved by training, sleep, alcohol intake, and energy balance, all of which are upstream of any pharmacologic intervention. The honest framing is that tesamorelin has clear label-grade evidence in a specific population and a thinner literature elsewhere .

Monitoring and IGF-1

Tesamorelin elevates IGF-1 by design. The Egrifta WR label directs IGF-1 monitoring at baseline, after initiation, and periodically thereafter. The label specifies discontinuation considerations if IGF-1 exceeds the upper limit of normal for age and sex, and includes pre-existing diabetes and impaired glucose tolerance among the populations requiring closer monitoring .

Glucose tolerance can shift on GH-axis-active therapy. The pivotal trials reported small mean changes in fasting glucose and HbA1c that were within the margin of pre-existing diabetes management for most subjects, but individual responses vary. Off-label use without IGF-1 and glycemic monitoring is a meaningful safety gap.

Label contraindications and warnings

• Disrupted hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, head trauma).
• Active malignancy (any newly diagnosed or pre-existing). The label cites the theoretical risk of GH/IGF-1 acceleration of occult malignancy.
• Pregnancy: tesamorelin is contraindicated in pregnancy; rodent reproduction studies showed adverse effects.
• Known hypersensitivity to tesamorelin or mannitol.
• Critical illness (acute severe illness): GH-axis activation is associated with increased mortality in critically ill patients receiving high-dose GH; the label flags critical illness as a contraindication for the same reason.

Anti-doping posture

Tesamorelin sits within WADA prohibited-list section S2 (peptide hormones, growth factors, related substances and mimetics), specifically in the GHRH analogs subgrouping. S2 substances are prohibited at all times, in and out of competition . USADA has explicitly addressed GHRH analogs including tesamorelin in athlete-advisory communications .

Athletes subject to WADA jurisdiction should treat tesamorelin as prohibited. A therapeutic-use exemption is theoretically available but is rarely granted for off-label use; HIV-associated lipodystrophy in a competing athlete would be the relevant TUE pathway.

Product history: Egrifta, Egrifta SV, Egrifta WR

The original Egrifta (2010) used a multi-vial reconstitution protocol with sterile water for injection. Egrifta SV (Single Vial, 2019) consolidated the reconstitution into a single 2 mg vial that delivered a 1.4 mg dose. The current product, Egrifta WR (Water Reconstitution), simplified storage and reconstitution further and replaced the earlier formulations on the US market. Importantly, the dose strengths and reconstitution protocols differ across product generations, so dosing instructions are not interchangeable across labels .

Compounded tesamorelin from non-FDA-overseen sources is a separate category. The FDA-approved label and trial data discussed throughout this article apply to the labeled product, not to compounded preparations of unverified identity, concentration, or sterility.

What would actually move the off-label evidence map

• A randomized phase 2/3 trial of tesamorelin in non-HIV adults with NAFLD and central adiposity, with MRI-PDFF as the primary endpoint and IGF-1 / glycemic safety as secondary endpoints.
• A long-term cardiovascular outcomes trial, since the existing trials were 26-52 weeks and not powered for MACE.
• Clear comparative data versus pure exercise / dietary visceral-fat interventions in matched populations.
• Long-term IGF-1 surveillance data on chronic dosing for safety on malignancy and glucose tolerance.

Editorial summary

Tesamorelin is one of the most rigorously studied peptides in this catalog within its label. Outside its label, the evidence base is thinner, the safety monitoring is rarely replicated by users, and the cost of self-directed use compares unfavorably to upstream interventions on training, sleep, and energy balance.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.